Insmed Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Insmed kazanç ve gelirin sırasıyla yıllık 54.4% ve 49.4% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 55.7% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde -139% olacağı tahmin edilmektedir.

Anahtar bilgiler

54.4%

Kazanç büyüme oranı

55.7%

EPS büyüme oranı

Biotechs kazanç büyümesi	28.3%
Gelir büyüme oranı	49.4%
Gelecekteki özkaynak getirisi	-139.0%
Analist kapsamı	Good
Son güncelleme	22 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Insmed Incorporated (NASDAQ:INSM) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Feb 25

Insmed Incorporated (NASDAQ:INSM) Investors Are Less Pessimistic Than Expected

Dec 18

Getting In Cheap On Insmed Incorporated (NASDAQ:INSM) Is Unlikely

Jul 28

Calculating The Intrinsic Value Of Insmed Incorporated (NASDAQ:INSM)

Jul 01

Would Insmed (NASDAQ:INSM) Be Better Off With Less Debt?

Apr 18

A Look At The Fair Value Of Insmed Incorporated (NASDAQ:INSM)

Feb 23

Insmed inks financing agreements to raise $500M

Oct 19

Does Insmed (NASDAQ:INSM) Have A Healthy Balance Sheet?

Oct 17

An Intrinsic Calculation For Insmed Incorporated (NASDAQ:INSM) Suggests It's 46% Undervalued

Sep 20

Insmed rises 16% on better-than-expected Q2 result

Aug 04

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:INSM - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	1,029	-498	-488	-253	15
12/31/2025	507	-814	-791	-794	17
12/31/2024	357	-883	-755	-653	17
9/30/2024	343	-864	-636	-619	N/A
6/30/2024	329	-803	-591	-574	N/A
3/31/2024	315	-747	-589	-574	N/A
12/31/2023	305	-750	-550	-536	N/A
9/30/2023	281	-724	-524	-509	N/A
6/30/2023	269	-696	-476	-462	N/A
3/31/2023	257	-547	-453	-442	N/A
12/31/2022	245	-482	-410	-400	N/A
9/30/2022	242	-434	-388	-381	N/A
6/30/2022	221	-416	-374	-367	N/A
3/31/2022	201	-438	-348	-340	N/A
12/31/2021	188	-435	-371	-363	N/A
9/30/2021	174	-424	-354	-346	N/A
6/30/2021	171	-375	-336	-329	N/A
3/31/2021	168	-319	-295	-290	N/A
12/31/2020	164	-294	-226	-219	N/A
9/30/2020	169	-245	-215	-197	N/A
6/30/2020	164	-242	-223	-191	N/A
3/31/2020	151	-247	-276	-235	N/A
12/31/2019	136	-254	-293	-251	N/A
9/30/2019	101	-293	-310	-276	N/A
6/30/2019	62	-320	-311	-290	N/A
3/31/2019	32	-330	-278	-264	N/A
12/31/2018	10	-324	-273	-258	N/A
9/30/2018	N/A	-298	-248	-236	N/A
6/30/2018	N/A	-256	N/A	-209	N/A
3/31/2018	N/A	-224	N/A	-190	N/A
12/31/2017	N/A	-193	N/A	-160	N/A
9/30/2017	N/A	-196	N/A	-169	N/A
6/30/2017	N/A	-188	N/A	-162	N/A
3/31/2017	N/A	-180	N/A	-154	N/A
12/31/2016	N/A	-176	N/A	-147	N/A
9/30/2016	N/A	-139	N/A	-116	N/A
6/30/2016	N/A	-132	N/A	-109	N/A
3/31/2016	N/A	-124	N/A	-105	N/A
12/31/2015	N/A	-118	N/A	-101	N/A
9/30/2015	N/A	-105	N/A	-86	N/A
6/30/2015	N/A	-98	N/A	-83	N/A
3/31/2015	N/A	-92	N/A	-77	N/A
12/31/2014	N/A	-79	N/A	-64	N/A
9/30/2014	N/A	-78	N/A	-66	N/A
6/30/2014	N/A	-71	N/A	-61	N/A
3/31/2014	N/A	-57	N/A	-48	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: INSM önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: INSM önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: INSM önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: INSM şirketinin gelirinin (yıllık 49.4% ) US pazarından (yıllık 8.9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: INSM şirketinin gelirinin (yıllık 49.4% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: INSM 3 yıl içinde kârsız olması bekleniyor.

Insmed Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Insmed Incorporated Reiterates earnings Guidance for the Year 2024

Consensus EPS estimates fall by 11%, revenue upgraded

Insmed Incorporated Reiterates Revenue Guidance for the Year 2024

Price target increased by 8.7% to US$82.63

Price target increased by 7.0% to US$73.44

Price target increased by 25% to US$56.56

Recent updates

Insmed: PAH Treatment Advancement With 2nd Half 2025 Top-Line Data

Insmed Incorporated has withdrawn its Follow-on Equity Offering in the amount of $500 million.

Insmed Incorporated Reiterates earnings Guidance for the Year 2024

Third quarter 2024 earnings: EPS misses analyst expectations

Insmed Incorporated to Report Q3, 2024 Results on Oct 31, 2024

Insmed Incorporated Presents New Subgroup Analyses from Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis Demonstrate Consistency with Positive Overall Trial Population Results

Insmed Incorporated's (NASDAQ:INSM) Share Price Not Quite Adding Up

Chief Medical Officer notifies of intention to sell stock

Insmed: Brensocatib Propels Stock As Regulatory Milestones Approach

Chief People Strategy Officer recently sold US$686k worth of stock

Consensus EPS estimates fall by 11%, revenue upgraded

Insider notifies of intention to sell stock

Is Insmed (NASDAQ:INSM) A Risky Investment?

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Insmed Incorporated Reiterates Revenue Guidance for the Year 2024

Insmed Incorporated to Report Q2, 2024 Results on Aug 08, 2024

Price target increased by 8.7% to US$82.63

Insmed Incorporated Announces Additional Positive Results from the ASPEN Study

Price target increased by 7.0% to US$73.44

Chief Medical Officer exercised options and sold US$768k worth of stock

Insmed Incorporated has completed a Follow-on Equity Offering in the amount of $649.999989 million.

Chief Financial Officer notifies of intention to sell stock

Price target increased by 25% to US$56.56

Insmed Incorporated has filed a Follow-on Equity Offering in the amount of $500 million.

Insmed Incorporated's (NASDAQ:INSM) 92% Share Price Surge Not Quite Adding Up

Insmed Incorporated Announces Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with Bronchiectasis

New major risk - Share price stability

Insmed Strikes Gold With Phase 3 Bronchiectasis Win (Rating Upgrade)

Insmed Incorporated Presents Positive Patient-Reported Outcomes and Microbiologic Data from Phase 3 Arise Study of Arikayce in Patients with NTM Lung Disease at American Thoracic Society 2024 International Conference Plenary Session

President recently sold US$566k worth of stock

President notifies of intention to sell stock

New major risk - Financial position

Insmed Incorporated to Report Q1, 2024 Results on May 09, 2024

Insmed Incorporated, Annual General Meeting, May 13, 2024

Insmed Incorporated to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International Conference

President exercised options to buy US$1.4m worth of stock.

Insmed Incorporated (NASDAQ:INSM) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Full year 2023 earnings: EPS misses analyst expectations

Insmed Incorporated has filed a Follow-on Equity Offering in the amount of $500 million.

Insmed Incorporated to Report Q4, 2023 Results on Feb 22, 2024

President notifies of intention to sell stock

Insmed Incorporated Provides Sales Guidance for the Full Year 2023 and 2024

Chief Medical Officer notifies of intention to sell stock

Insmed Incorporated (NASDAQ:INSM) Investors Are Less Pessimistic Than Expected

President notifies of intention to sell stock

Third quarter 2023 earnings: EPS exceeds analyst expectations

Insmed Incorporated to Report Q3, 2023 Results on Oct 26, 2023

Insmed Incorporated Announces Positive Topline Results from Phase 3 Arise Study of Arikayce® (Amikacin Liposome Inhalation Suspension) in Patients with Ntm Lung Disease Caused by Mac

Consensus EPS estimates fall by 14%, revenue upgraded

Insmed Incorporated (NasdaqGS:INSM) acquired Adrestia Therapeutics Ltd.

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Getting In Cheap On Insmed Incorporated (NASDAQ:INSM) Is Unlikely

Insmed Incorporated to Report Q2, 2023 Results on Aug 03, 2023

Calculating The Intrinsic Value Of Insmed Incorporated (NASDAQ:INSM)

Chief Commercial Officer recently sold US$64k worth of stock

Insmed Incorporated Presents Range of New Study Findings at American Thoracic Society 2023 International Conference

Senior VP recently sold US$68k worth of stock

President exercised options to buy US$4.3m worth of stock.

Insmed Incorporated Unveils New Research Platforms and Capabilities at Investor and Analyst Event

Insmed Incorporated Provides Revenue Guidance for the Full-Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Would Insmed (NASDAQ:INSM) Be Better Off With Less Debt?

Full year 2022 earnings released: US$3.91 loss per share (vs US$3.88 loss in FY 2021)

A Look At The Fair Value Of Insmed Incorporated (NASDAQ:INSM)

Insmed Incorporated to Report Q4, 2022 Results on Feb 23, 2023

Chief Financial Officer notifies of intention to sell stock

President recently sold US$139k worth of stock

Insufficient new directors

Independent Director recently bought US$796k worth of stock